Synthetic lethal drug combination for treating renal cell carcinoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10322133
APP PUB NO 20180256587A1
SERIAL NO

15759815

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESPARIS FRANCE PARIS PARIS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barette, Caroline Sassenage, FR 5 3
Cochet, Claude Claix, FR 9 15
Filhol, Odile Claix, FR 2 0
Giacosa, Sofia La Tour du Pin, FR 1 0
Pillet, Catherine Vif, FR 2 0
Soleilhac, Emmanuelle Saint Etienne de Crossy, FR 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 18, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 18, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00